Comparative Pharmacology
Head-to-head clinical analysis: AVZIVI versus LUCENTIS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AVZIVI versus LUCENTIS.
AVZIVI vs LUCENTIS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Avizivi (avelumab) is a human IgG1 monoclonal antibody that binds to programmed death-ligand 1 (PD-L1), blocking its interaction with PD-1 and CD80 receptors. This restores anti-tumor immune responses, including T-cell activation and proliferation, by reversing PD-L1-mediated inhibition.
Ranibizumab is a recombinant humanized monoclonal antibody fragment that binds to and inhibits the biological activity of vascular endothelial growth factor A (VEGF-A), thereby preventing VEGF-A from interacting with its receptors (VEGFR1 and VEGFR2) on endothelial cells, reducing neovascularization and vascular permeability.
IV 200 mg over 30 minutes on Day 1 of a 21-day cycle, in combination with paclitaxel and carboplatin; continue until disease progression or unacceptable toxicity.
Intravitreal injection of 0.5 mg (0.05 mL) once every 4 weeks (monthly).
None Documented
None Documented
Terminal elimination half-life is approximately 12 hours (range 10–14 h) in patients with normal renal function; prolonged to 24–48 h in moderate-to-severe renal impairment.
Terminal elimination half-life from vitreous humor: approximately 9 days (range 7–11 days) in humans. From serum: ~0.5 days (due to rapid systemic clearance). Clinical context: supports monthly intravitreal dosing.
Primarily renal excretion as unchanged drug (~70%) and glucuronide conjugate (~30%); biliary/fecal excretion accounts for <5%.
Primarily metabolized via catabolism to small peptides and amino acids; renal excretion of intact drug is negligible due to high molecular weight (48 kDa). Fecal/biliary elimination not characterized. Systemic clearance ~0.81 mL/hr.
Category C
Category C
VEGF Inhibitor
VEGF Inhibitor